Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leslie Burnett has a total of 359 co-authors. Here are the top co-authors by number of shared publications:

  • Anné L Proos

    NSW Health Pathology North, Royal North Shore Hospital, St Leonards, Australia

    4 shared publications
  • Douglas Chesher

    Pathology North, NSW Health Pathology, Royal North Shore Hospital, St Leonards, NSW, 2065, Australia;; Northern Clinical School, Sydney Medical School, University of Sydney, NSW, 2006, Australia

    4 shared publications
  • Mia J. Gruzin

    Garvan Institute of Medical Research, Darlinghurst, NSW, Australia; School of Clinical Medicine, UNSW Medicine and Health, St Vincent's Clinical Healthcare Campus, Darlinghurst, NSW, Australia

    4 shared publications
  • Raelia Lew

    Department of Obstetrics and Gynecology, QEII Research Institute for Mothers and Infants, The University of Sydney, Australia ; Department of Obstetrics and Gynaecology, Dentistry and Health Sciences, Faculty of Medicine, The University of Melbourne, Melbourne, Australia

    4 shared publications
  • William J. Hensley

    Department of Clinical Biochemistry, Royal Prince Alfred Hospital Missenden Road, Camperdown, NSW 2050, Australia

    4 shared publications
  • Antony Basten

    Clinical Immunology Research Centre, Royal Prince Alfred Hospital Missenden Road, Camperdown, NSW, 2050, Australia

    3 shared publications

Latest Publications

  • Open Access

    Ensuring equity in reproductive carrier screening of CFTR with increasing population diversity

    by Mia J. Gruzin, Jaysen Knezovich, Sarah Poll, Nicole Schonrock, Swaroop Aradhya, Leslie Burnett

  • Open Access

    A Multitrait Polygenic Risk Score for Open-Angle Glaucoma Stratifies Risk of Pigmentary Glaucoma in Pigment Dispersion Syndrome

    by Antonia Kolovos, Ayub Qassim, Henry N. Marshall, Thi Thi Nguyen, Joshua Schmidt, Mark M. Hassall, Victoria Tang, Giorgina Maxwell, John Landers, Richard Mills, et al.

  • Open Access

    A dataset of estimated heterozygous individual and carrier couple frequencies for pan-ancestry carrier screening

    by Mia J. Gruzin, Matthew Hobbs, Sarah Poll, Swaroop Aradhya, Leslie Burnett


  • Open Access

    Optimizing gene panels for equitable reproductive carrier screening: The Goldilocks approach

    by Mia J. Gruzin, Matthew Hobbs, Rachel E. Ellsworth, Sarah Poll, Sienna Aguilar, Jaysen Knezovich, Nicole Faulkner, Nick Olsen, Swaroop Aradhya, Leslie Burnett


  • Top Cited Papers

    Nationwide, Couple-Based Genetic Carrier Screening

    by Edwin P. Kirk, Martin B. Delatycki, Alison D. Archibald, Erin Tutty, Jade Caruana, Jane L. Halliday, Sharon Lewis, Belinda J. McClaren, Ainsley J. Newson, Lisa Dive, et al.

    Genomic sequencing technology allows for identification of reproductive couples with an increased chance, as compared with that in the general population, of having a child with an autosomal recessive or X-linked genetic condition. We investigated the feasibility, acceptability, and outcomes of a nationwide, couple-based genetic carrier screening program in Australia as part of the Mackenzie's Mission project. Health care providers offered screening to persons before pregnancy or early in pregnancy. The results obtained from testing at least 1281 genes were provided to the reproductive couples. We aimed to ascertain the psychosocial effects on participants, the acceptability of screening to all participants, and the reproductive choices of persons identified as having an increased chance of having a child with a condition for which we screened. Among 10,038 reproductive couples enrolled in the study, 9107 (90.7%) completed screening, and 175 (1.9%) were newly identified as having an increased chance of having a child with a genetic condition for which we screened. These conditions involved pathogenic variants in 90 different genes; 74.3% of the conditions were autosomal recessive. Three months after receiving the results, 76.6% of the couples with a newly identified increased chance had used or planned to use reproductive interventions to avoid having an affected child. Those newly identified as having an increased chance had greater anxiety than those with a low chance. The median level of decisional regret was low in all result groups, and 98.9% of participants perceived screening to be acceptable. Couple-based reproductive genetic carrier screening was largely acceptable to participants and was used to inform reproductive decision making. The delivery of screening to a diverse and geographically dispersed population was feasible. (Funded by the Medical Research Future Fund of the Australian government; ClinicalTrials.gov number, NCT04157595.).


  • Open Access

    Genomic Testing in Patients with Kidney Failure of an Unknown Cause

    by Amali C. Mallawaarachchi, Lindsay Fowles, Louise Wardrop, Alasdair Wood, Rosie O'SHea, Erik Biros, Trudie Harris, Stephen I. Alexander, Simon Bodek, Neil Boudville, et al.

    Key Points: Twenty-five percent of those with unexplained kidney failure have a monogenic cause. Whole genome sequencing with broad gene panel analysis is a feasible diagnostic approach in nephrology. Background: The cause of kidney failure is unknown in approximately 10% of patients with stage 5 chronic kidney disease (CKD). For those who first present to nephrology care with kidney failure, standard investigations of serology, imaging, urinalysis, and kidney biopsy are limited differentiators of etiology. We aimed to determine the diagnostic utility of whole genome sequencing (WGS) with analysis of a broad kidney gene panel in patients with kidney failure of unknown cause. Methods: We prospectively recruited 100 participants who reached CKD stage 5 at the age of ≤50 years and had an unknown cause of kidney failure after standard investigation. Clinically accredited WGS was performed in this national cohort after genetic counseling. The primary analysis was targeted to 388 kidney-related genes with second-tier, genome-wide, and mitochondrial analysis. Results: The cohort was 61% male and the average age of participants at stage 5 CKD was 32 years (9 months to 50 years). A genetic diagnosis was made in 25% of participants. Disease-causing variants were identified across autosomal dominant tubulointerstitial kidney disease (6), glomerular disorders (4), ciliopathies (3), tubular disorders (2), Alport syndrome (4), and mitochondrial disease (1). Most diagnoses (80%) were in autosomal dominant, X-linked, or mitochondrial conditions (UMOD; COL4A5; INF2; CLCN5; TRPC6; COL4A4; EYA1; HNF1B; WT1; NBEA; m.3243A>G). Participants with a family history of CKD were more likely to have a positive result (odds ratio, 3.29; 95% confidence interval, 1.10 to 11.29). Thirteen percent of participants without a CKD family history had a positive result. In those who first presented in stage 5 CKD, WGS with broad analysis of a curated kidney disease gene panel was diagnostically more informative than kidney biopsy, with biopsy being inconclusive in 24 of the 25 participants. Conclusions: In this prospectively ascertained Australian cohort, we identified a genetic diagnosis in 25% of patients with kidney failure of unknown cause.


  • Open Access

    Community Genetics screening in a pandemic: solutions for pre-test education, informed consent, and specimen collection

    by Bronwyn Terrill, Lauren McKnight, Angela Pearce, Heather Gordon, William Lo, I-Chieh Jennifer Lee, Monica Runiewicz, Alex Palmer, Lesley Andrews, Edwin Kirk, et al.

    A Community Genetics carrier screening program for the Jewish community has operated on-site in high schools in Sydney (Australia) for 25 years. During 2020, in response to the COVID-19 pandemic, government-mandated social-distancing, ‘lock-down’ public health orders, and laboratory supply-chain shortages prevented the usual operation and delivery of the annual testing program. We describe development of three responses to overcome these challenges: (1) pivoting to online education sufficient to ensure informed consent for both genetic and genomic testing; (2) development of contactless telehealth with remote training and supervision for collecting genetic samples using buccal swabs; and (3) a novel patient and specimen identification ‘GeneTrustee’ protocol enabling fully identified clinical-grade specimens to be collected and DNA extracted by a research laboratory while maintaining full participant confidentiality and privacy. These telehealth strategies for education, consent, specimen collection and sample processing enabled uninterrupted delivery and operation of complex genetic testing and screening programs even amid pandemic restrictions. These tools remain available for future operation and can be adapted to other programs.


  • Open Access

    The Australian Reproductive Genetic Carrier Screening Project (Mackenzie’s Mission): Design and Implementation

    by Alison D. Archibald, Belinda J. McClaren, Jade Caruana, Erin Tutty, Emily A. King, Jane L. Halliday, Stephanie Best, Anaita Kanga-Parabia, Bruce H. Bennetts, Corrina C. Cliffe, et al.

    Reproductive genetic carrier screening (RGCS) provides people with information about their chance of having children with autosomal recessive or X-linked genetic conditions, enabling informed reproductive decision-making. RGCS is recommended to be offered to all couples during preconception or in early pregnancy. However, cost and a lack of awareness may prevent access. To address this, the Australian Government funded Mackenzie’s Mission—the Australian Reproductive Genetic Carrier Screening Project. Mackenzie’s Mission aims to assess the acceptability and feasibility of an easily accessible RGCS program, provided free of charge to the participant. In study Phase 1, implementation needs were mapped, and key study elements were developed. In Phase 2, RGCS is being offered by healthcare providers educated by the study team. Reproductive couples who provide consent are screened for over 1200 genes associated with >750 serious, childhood-onset genetic conditions. Those with an increased chance result are provided comprehensive genetic counseling support. Reproductive couples, recruiting healthcare providers, and study team members are also invited to complete surveys and/or interviews. In Phase 3, a mixed-methods analysis will be undertaken to assess the program outcomes, psychosocial implications and implementation considerations alongside an ongoing bioethical analysis and a health economic evaluation. Findings will inform the implementation of an ethically robust RGCS program.


  • Open Access

    Evaluating the model of offering expanded genetic carrier screening to high school students within the Sydney Jewish community

    by Kristine Barlow-Stewart, Kayley Bardsley, Elle Elan, Jane Fleming, Yemima Berman, Ron Fleischer, Krista Recsei, Daniel Goldberg, John Tucker, Leslie Burnett

    Programs offering reproductive genetic carrier screening (RGCS) to high school students within the Ashkenazi Jewish community in several countries including Canada and Australia have demonstrated high uptake and retention of educational messages over time. This study was undertaken to evaluate whether testing for an expanded number of conditions in a high school setting would impact the effectiveness of education. In this questionnaire-based study, genetic carrier testing for nine conditions was offered to 322 year 11 students from five high schools, with students attending a compulsory 1-h education session prior to voluntary testing. Comparison of pre- and post-education measures demonstrated a significant increase in knowledge, positive attitudes, and reduced concern immediately after the education session. Retention of knowledge, measures of positive attitude, and low concern over a 12-month period were significantly higher than baseline, although there was some reduction over time. In total, 77% of students exhibited informed choice regarding their intention to test. A significant increase in baseline knowledge scores and positive attitude was also demonstrated between our original 1995 evaluation (with testing for only one condition) and 2014 (testing for nine conditions) suggesting community awareness and attitudes to RGCS have increased. These findings validate the implementation of effective education programs as a key component of RGCS and are relevant as gene panels expand with the introduction of genomic technologies.